NCT06379646
An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
At risk: Primary completion moved 2 years later.
See at-risk trials from China Immunotech (Beijing) Biotechnology Co., Ltd.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion dates pushed to Apr 21, 2027 Show 6 more changesShow less
- Start date pushed from Apr 24, 2024 to Oct 24, 2024
- Eligibility criteria expanded, about 49 words
- Primary endpoints: details revised at 1 of 7 entries
- Trial status changed: Unknown → Recruiting
- Secondary endpoints: details revised at 6 of 10 entries
- Publications: details revised at 1 of 1 entry
- Minor Changed Registry marked status Unknown; last known: Recruiting
- Notable Primary endpoints revised (7)
- Trial status: Recruiting to Unknown
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
- Eligibility criteria expanded, about 11 words
- Study sites: 0 to 1
- Start date changed from estimate of Apr 22, 2024 to Apr 24, 2024
- Secondary endpoints: 4 to 10
- Study description shortened, about 17 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Timeframe: 3 months for safety measurements during the treatment assessment period
Efficacy outcomes for SLE
Timeframe: 3 months for efficacy measurements during the treatment assessment period
Efficacy outcomes for Sjogren's Syndrome
Timeframe: 3 months for efficacy measurements during the treatment assessment period
Efficacy outcomes for Systemic Sclerosis
Timeframe: 3 months for efficacy measurements during the treatment assessment period
Efficacy outcomes for Inflammatory Myopathy
Timeframe: 3 months for efficacy measurements during the treatment assessment period
Efficacy outcomes for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Timeframe: 3 months for efficacy measurements during the treatment assessment period
Efficacy outcomes for Antiphospholipid Syndrome
Timeframe: 3 months for efficacy measurements during the treatment assessment period
Secondary (10)
Peak Plasma Concentration (Cmax) of YTS109
Time to Peak (Tmax) of YTS109
Area under the plasma concentration versus time curve (AUC) of YTS109
PD parameters
Efficacy outcomes for SLE
Show 5 moreShow less
Efficacy outcomes for Sjogren's Syndrome
Efficacy outcomes for Systemic Sclerosis
Efficacy outcomes for Inflammatory Myopathy
Efficacy outcomes for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Efficacy outcomes for Antiphospholipid Syndrome
Arms and interventions
YTS109Experimental
YTS109 cell injection
Other: YTS109
Sites
1 site in 1 country
- Shanghai Changzheng HospitalShanghai, Shanghai Municipality, China